Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 17/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 16/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 12/20 | 0.77 |
| ▸ | HTR2B | P41595 | 6/20 | 0.77 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.77 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.75 |
| ▸ | HTR2C | P28335 | 3/20 | 0.73 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25612586 | 0.90 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMEM97 | |
| SCHEMBL3740327 | 0.87 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMEM97 | |
| SCHEMBL13276340 | 0.84 | ADORA3 (0.78) | ADORA3ADORA1ADORA2AHTR2BTMEM97 | |
| SCHEMBL19807417 | 0.82 | ADORA3 (0.84) | ADORA3ADORA1ADORA2AHTR2BTMEM97 | |
| SCHEMBL3728539 | 0.82 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BHSP90B1 | |
| SCHEMBL3729915 | 0.81 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2B | |
| SCHEMBL3730113 | 0.80 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2B | |
| SCHEMBL3734220 | 0.80 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2B | |
| SCHEMBL13388428 | 0.80 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL3740313 | 0.80 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916570-B2 | A3 adenosine receptor agonists and antagonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-12-23 | — | — | US | disclosed |
| EP-2260038-B1 | PURINE DERIVATIVES AS A3 ADENOSINE RECEPTOR-SELECTIVE AGONISTS | US HEALTH (US) | 2014-12-03 | — | — | EP | disclosed |
| US-8735407-B2 | Purine derivatives as A3 adenosine receptor-selective agonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-05-27 | — | — | US | disclosed |
| US-20120184569-A1 | A3 ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2012-07-19 | — | — | US | disclosed |
| US-20110046166-A1 | PURINE DERIVATIVES AS A3 ADENOSINE RECEPTOR-SELECTIVE AGONISTS | Office of Technology Transfer, NIH (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046166-A1 | PURINE DERIVATIVES AS A3 ADENOSINE RECEPTOR-SELECTIVE AGONISTS | ADORA3, ADORA1, ADORA2A | ADORA3 1/4885ADORA1 2/4885ADORA2A 3/4885 |
| US-20120184569-A1 | A3 ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS | ADORA3, ADORA1, ADORA2A | ADORA3 1/4885ADORA1 2/4885ADORA2A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.